CliffBio
biologic

Avsola

infliximab-axxq

Loss of exclusivity—loss of exclusivity
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameAvsola
Active ingredientinfliximab-axxq
Strength100MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2019
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Avsola patent cliff — loss of exclusivity — | CliffBio